Recent 8-K filings for DSGN
Highest-materiality recent filing
Design Therapeutics reports positive Phase 1/2 data for DT-216P2 in Friedreich ataxia
- After 4 weeks at 1 mpk, mFARS improved 6.4 points, Upright Stability Score 2.7 points, fatigue >5 points (PROMIS).
- Whole blood FXN mRNA increased 65% (p<0.001); muscle FXN mRNA up 42% (p=0.015); FXN protein increased 22-27%.
-
Design Therapeutics reports positive Phase 1/2 data for DT-216P2 in Friedreich ataxia
After 4 weeks at 1 mpk, mFARS improved 6.4 points, Upright Stability Score 2.7 points, fatigue >5 points (PROMIS).
-
Design Therapeutics Q1 net loss $17.6M; cash $222.8M funds ops into 2029; pipeline on track
Net loss of $17.6M for Q1 2026; R&D expense $14.4M, G&A $5.3M.
-
Design Therapeutics appoints Dr. David Shapiro to Board as Class III director
Dr. David Shapiro appointed to Board effective Mar 31, 2026, as Class III director with term through 2027 annual meeting.
-
Design Therapeutics reports Q4 2025 net loss of $16.0M; cash $219.8M funds operations into 2029
Full-year 2025 net loss $69.8M; R&D expenses $59.1M, G&A $20.3M.
-
Design Therapeutics board member Deepa Prasad resigns effective Feb 1, 2026
Deepa Prasad resigned from Design Therapeutics Board of Directors effective February 1, 2026.
-
Design Therapeutics plans DT-818 DM1 trial H1 2026; Q3 net loss $17M; cash $206M
DT-818 nominated as DM1 development candidate; >90% reduction in toxic RNA foci in preclinical studies.
-
Design Therapeutics director resigns; Justin Gover appointed to board
Arsani William, M.D. resigned from board effective Sept 9, 2025, not due to any disagreement.
-
Design Therapeutics Q2 net loss $19.1M; FDA clinical hold on DT-216P2 US IND; cash $216.3M
Net loss of $19.1M for Q2 2025; R&D expense $15.7M, G&A $5.8M; cash and securities $216.3M as of June 30, 2025.
-
Design Therapeutics stockholders elect directors and ratify auditor at 2025 annual meeting
Heather Berger, Ph.D., Rodney Lappe, Ph.D., and John Schmid elected as Class I directors to serve until 2028 annual meeting.
-
Design Therapeutics Q1 net loss $17.7M; cash $229.7M funds into 2029
R&D expenses $15.4M, G&A $5.0M for Q1 2025; net loss $17.7M.
-
Design Therapeutics Q4 2024 net loss $13.7M; cash $245.5M; FA and FECD trials advancing
Net loss of $13.7M for Q4 2024 and $49.6M for full year 2024; R&D expense $44.4M, G&A $18.0M.
-
Design Therapeutics updates corporate presentation with no material new information
Updated corporate presentation filed as Exhibit 99.1 for use in investor meetings.
-
Design Therapeutics Q3 net loss $13.0M; FECD Phase 1 trial initiated, data H1 2025
Net loss of $13.0M for Q3 2024; R&D expense $11.9M, G&A expense $4.4M.
-
Design Therapeutics Q2 net loss $11.8M; cash $261M; FA and FECD programs on track
Net loss $11.8M for Q2 2024; R&D expense $10.5M, G&A expense $4.5M.
-
Design Therapeutics stockholders elect Pratik Shah as Class III director, ratify EY auditor
Pratik Shah, Ph.D. elected as Class III director with ~42.8M votes for, ~3.5M withheld (7.7M broker non-votes).
-
Design Therapeutics Q1 net loss $11.1M; cash $270.7M; advancing DT-216P2, DT-168, HD, DM1 programs
Net loss of $11.1M for Q1 2024; R&D expenses $9.8M, G&A expenses $4.6M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.55 · Most common event earnings